Peptides DB

Research-centric peptide and protocol reference hub

Anti-Aging Peptide Stack: What the Evidence Actually Supports

Most 'anti-aging peptide stacks' over-promise. Here's a defensible combination — NAD+, GHK-Cu, Epitalon, SS-31 — with what each does, what the evidence supports, and what's speculative.

Published Jun 14, 20266 min read

Most "anti-aging peptide stacks" combine compounds with strong mechanistic stories and weak human-trial data. The defensible combination is built around NAD+ (and precursors), Epitalon for telomerase signaling, GHK-Cu for skin and connective-tissue regeneration, and SS-31 for mitochondrial protection. None of these is proven to extend human lifespan; some have meaningful evidence for specific aging-related endpoints. This article covers what's defensible, what's speculative, and how to think about the stack honestly.

For the broader landscape see /peptides/category/longevity and /peptides/category/anti-aging.

What we actually know

The honest version: no peptide or peptide stack has been demonstrated to extend healthy human lifespan in controlled trials. The evidence base is:

  • Strong: Compound X improves a specific biomarker (telomere length, NAD+ levels, mitochondrial function, skin elasticity, etc.) in humans over weeks to months.
  • Moderate: Compound X delays or reverses a specific aging-related disease endpoint in mice.
  • Weak: Compound X is "anti-aging" generally.

The stack below is built on the strong and moderate categories — endpoints that are measurable and have published data — not on the weak general "anti-aging" framing.

The defensible four-peptide stack

1. NAD+ (or precursors NMN, NR)

Why it's in the stack: NAD+ (nicotinamide adenine dinucleotide) declines with age across nearly every tissue measured. NAD+ is required for sirtuin function (longevity-associated genes), PARP function (DNA repair), and mitochondrial energy production. Restoring NAD+ levels via the cofactor itself, NMN, or NR has measurable effects on energy metabolism in published human studies.

What the evidence shows: Multiple Phase 1 / Phase 2 trials of NAD+, NMN, and NR demonstrate that supplementation raises blood NAD+ levels measurably. Downstream clinical effects (functional improvements, biomarker shifts) are more mixed — some trials positive, some null.

Format: Oral NMN or NR is the most common route; IV NAD+ infusion is used in some specialty clinics; SC NAD+ injection has limited published data.

Dose: NMN 250–500 mg daily oral; NAD+ IV 500–1000 mg per infusion (weekly to monthly).

NAD+ research profile.

2. Epitalon

Why it's in the stack: Epitalon (also Epithalon or Epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on a pineal-gland extract. The strongest mechanistic story is telomerase activation — in human cell-culture and animal studies it upregulates telomerase reverse transcriptase (TERT) and lengthens telomeres.

What the evidence shows: Russian gerontological studies across 20+ years suggest reduced all-cause mortality and improved age-related biomarkers in elderly populations on annual Epitalon courses. The studies are smaller and methodologically less rigorous than Western Phase 2/3 trials; the signal is consistent but not definitive.

Format: Subcutaneous injection.

Dose: 5–10 mg daily for a 10–20 day course, once or twice per year (annual or semi-annual cycling pattern).

Epitalon research profile.

3. GHK-Cu (and AHK-Cu for hair)

Why it's in the stack: Skin and connective-tissue aging are visible markers of underlying connective-tissue decline. GHK-Cu has the strongest cosmetic-peptide evidence base for skin regeneration, fine-line reduction, and dermal repair.

What the evidence shows: Decades of topical cosmetic evidence. Injected use has weaker but plausible data for systemic skin-quality and tendon-healing endpoints.

Format: Topical (1–3% serum) primarily; subcutaneous injection in some research-use protocols.

Dose: Topical: 2× daily for 12+ weeks. Injected: 1–2 mg, 2–3× weekly subcutaneous in 4–8 week cycles.

GHK-Cu research profile. Copper peptides guide.

4. SS-31 (Elamipretide)

Why it's in the stack: SS-31 targets cardiolipin in the inner mitochondrial membrane and protects mitochondrial function. Cardiolipin damage and resulting mitochondrial dysfunction are core aging mechanisms.

What the evidence shows: Phase 2/3 clinical trials in primary mitochondrial myopathies (Barth syndrome, primary mitochondrial disease) showed measurable functional improvements. Trials in cardiovascular indications have been mixed. The longevity-specific evidence base is animal-data-heavy.

Format: Subcutaneous injection.

Dose: 5–10 mg subcutaneous daily during a 4–8 week cycle, with washouts.

SS-31 research profile.

Optional additions

Glutathione

Glutathione is a tripeptide (Cys-Gly-Glu) — the body's most-abundant intracellular antioxidant. Liposomal oral, IV, or sublingual formulations all increase intracellular levels measurably. Strong general-antioxidant story; less specific to longevity than the four above.

Useful add-on for users with measured high oxidative stress or as supportive nutrition during a longevity cycle.

MOTS-c

MOTS-c is a mitochondrial-derived peptide with a metabolic-improvement story (improved exercise capacity, insulin sensitivity in animal studies). Human data limited. Mechanism overlaps with SS-31's mitochondrial focus; adding both is redundant unless you specifically want the metabolic-improvement angle.

FOXO4-DRI

FOXO4-DRI is a peptidomimetic designed to disrupt the p53-FOXO4 interaction in senescent cells, triggering their selective apoptosis (a "senolytic"). Strong mechanistic story; very limited human data; high cost and limited availability.

The senolytic class is conceptually promising but practically immature. Not in the core stack.

What's NOT in the stack and why

  • Telomerase activators sold as "lifespan extenders" (TA-65 and similar) — weaker evidence than Epitalon, often more expensive.
  • High-dose resveratrol — promising in mice, mostly failed in human trials.
  • Generic "growth hormone for anti-aging" — off-label use, illegal to prescribe for this indication in the US, real cumulative risk at supraphysiologic doses.
  • Stem-cell injections — outside the peptide scope of this site, and the field is rife with under-evidenced clinics.

A representative annual protocol

A defensible 12-month plan, assuming clinician supervision and baseline labs:

Q1 (months 1–3): NAD+ cycle.

  • NMN 500 mg oral daily, or NAD+ IV 500 mg weekly.
  • Topical GHK-Cu serum 2× daily, daily.

Q2 (months 4–6): GH-axis support (optional).

Q3 (months 7–9): Mitochondrial support.

  • SS-31 5–10 mg SC daily for 4–6 weeks.
  • Continue topical GHK-Cu.

Q4 (months 10–12): Epitalon cycle.

  • Epitalon 5–10 mg SC daily for 10–20 days.
  • Continue topical GHK-Cu.

Labs: baseline at month 0, repeat at months 4, 8, 12. Biomarkers worth tracking: IGF-1, A1C, fasting glucose, lipid panel, hsCRP, and (if available) inflammatory markers or methylation-age tests.

The total annual cost lands in the $5,000–$15,000 range depending on which components are clinician-prescribed vs research-use, and depending on the IV / IM / SC vs topical breakdown.

What this stack will and won't do

Will:

  • Likely improve measurable biomarkers (NAD+ levels, IGF-1, skin elasticity).
  • Provide a structured protocol with clear monitoring points.
  • Address several distinct aging mechanisms (NAD+ depletion, telomere shortening, mitochondrial dysfunction, dermal aging).

Won't:

  • Extend healthy human lifespan in any proven way (no peptide has been demonstrated to do this).
  • Replace foundational lifestyle factors (sleep, training, diet, stress management) — these matter more than any peptide.
  • Eliminate aging-related disease risk.

The honest framing: this is a "do the things with biomarker evidence" protocol, not a "live to 150" protocol.

Safety frame

Peptide-stack-level monitoring becomes important:

  • Baseline labs as listed above.
  • IGF-1 if running any GH-axis component.
  • Cancer-history exclusion for IGF-1-driving compounds.
  • Watch interaction with chronic medications (blood thinners, immunosuppressants, GLP-1s).
  • Run one new compound at a time so attribution is possible.

See are peptides safe? and peptide side effects.

Where to go from here